TuHURA Biosciences, Inc. agreed to acquire Kintara Therapeutics, Inc. (NasdaqCM:KTRA) in a reverse merger transaction on April 2, 2024. Subject to the terms and conditions, at the effective time of the Merger Effective Time, each outstanding share of TuHURA common stock will be converted into shares of Kintara common stock. The merger agreement has been approved by the boards of directors of both companies.

Both buy side and sell side termination fees is $1 million. The transaction is subject to the Company Stockholder Approval of both companies, TuHURA having received an aggregate amount of cash no less than $20,000,000 from the offering of its Company Convertible Notes. The Merger is expected to be completed in the third quarter of 2024.

Steven M. Skolnick of Lowenstein Sandler LLP acted as legal advisor to Kintara Therapeutics, Inc. Curt P. Creely and Garrett F. Bishop of Foley & Lardner LLP acted as legal advisor to TuHURA Biosciences, Inc. Lucid Capital Markets, LLC is acting as the exclusive financial advisor to Kintara. H.C. Wainwright & Co. is acting as the exclusive financial advisor to TuHURA.